NASDAQ · SNSE
Healthcare · Biotechnology
$13.85
Down-$3.97 (-22.28%)
Updated Sep 10, 2026, 9:46 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SNSE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning SNSE.
SNSE research
Company profile and research snapshot.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 15, 2026 | BTIG | Buy | — |
| Jun 11, 2026 | BTIG | Buy | — |
| May 29, 2026 | Cantor Fitzgerald | Overweight | — |
| May 28, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| May 22, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 15, 2026
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the "Company"). The Company's common stock is expected to begin trading on the Nasdaq Capital
Benzinga · Jun 11, 2026
BTIG analyst Jeet Mukherjee initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces Price Target of $55.
Benzinga · Mar 30, 2026
Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(3.74) per share which beat the analyst consensus estimate of $(4.11) by 9 percent. This is a 39.68 percent increase over losses of $(6.20) per share
Benzinga · Mar 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNSE.
